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Review of the Literature 
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ABSTRACT   Approximately 170 million people are infected with Hepatitis C virus (HCV) worldwide5,6. It 
is estimated that roughly 80% of those infected suffer from persistent infection with HCV; this 
persistence of infection is progressive, and over time can lead to fibrosis, cirrhosis, and hepatocellular 
carcinoma7. Chronic inflammation and apoptotic deregulation are both hallmarks of chronic HCV 
infection, and many molecular pathways are initiated in both the innate and adaptive immune responses 
during infection with this viral pathogen. This review surveys some of the major molecular mechanisms 
responsible for the induction of chronic inflammation that occurs during HCV infection. 
 
Abbreviations: HCV, Hepatitis C virus; HSC, hepatic stellate cells; KC, Kupffer cells; HCC, 
hepatocellular carcinoma; TNF, tumor necrosis factor; AIM, apoptosis inhibitor of macrophage; IL-1β, 
Interleukin-1beta; PRR, pattern recognition receptor; TNF-α, tumor necrosis factor-alpha; NLR, Nod-like 
receptor; NLRP3, Nod-like receptor P3; TLR, toll-like receptor; NF-κB, nuclear factor-κB; HSPB8, heat 
shock protein 8; AID, activation-induced cytidine deaminase.  
  
 
INTRODUCTION 
Hepatitis C virus (HCV) is a single-stranded, 
positive-sense RNA virus that belongs to the 
family flaviviridae 1. During replication, a single 
polyprotein is cleaved into three structural (core, 
E1, and E2) and seven nonstructural (p7, NS2, 
NS3, NS4A, NS4B, NS5A, and NS5B) 
proteins2, some of which studies have shown to 
mediate inflammatory processes during  
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infection3. Inflammatory stimuli are responsible 
for causing the synthesis and secretion of 
various cytokines and chemokines4. 
Inflammatory stimuli can also cause responses 
in a number of liver cells, such as hepatocytes, 
hepatic stellate cells (HSCs), and Kupffer cells 
(KCs) 4. 
 
It is estimated that approximately 170 million 
people worldwide are infected with HCV 5,6. 
Nearly 80% of those infected are unable to clear 
the acute HCV infection, which results in 
chronic infection with the virus7. This can lead 
to fibrosis, liver cirrhosis, and hepatocellular 
carcinoma (HCC) 7. 
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It has been reported that the most important 
cause of chronic hepatitis, liver cirrhosis, and 
HCC is HCV infection8. Currently, it is thought 
that as the severity of fibrosis increases so too 
does the incidence of HCC, and the progression 
of fibrosis is thought to be attributed to 
inflammation and steatosis8.  
 
Inflammation is an important component of the 
innate immune response. Under physiological 
conditions, inflammation is of vital importance 
in order to maintain a homeostatic environment 
in the body; this protective immune response 
warrants the removal of detrimental stimuli and 
also repairs damaged tissue 9.  
 
However, chronic inflammation has the ability 
to cause destructive effects. The mechanisms 
that are responsible for chronic inflammation in 
chronic HCV infection are extremely complex, 
not yet fully understood, and include direct viral 
effects as well as indirect molecular pathways 4. 
HCV can evolve and generate mutations such 
that it is able to evade the immune responses of 
the host 10.  Furthermore, the fact that HCV is 
capable of establishing a persistent chronic 
infection showcases its ability to escape both the 
innate and adaptive immune responses during 
the course of infection.  
 
The Liver: A Major HCV Replication Site 
The liver acts as a filter for toxins and food 
antigens that may be ingested. Interestingly, the 
liver may be considered a site that is relatively 
tolerant to harmless antigens that are consumed. 
Under normal physiological conditions, the liver 
can selectively remove activated CD8+ 
(cytotoxic) T cells that have specificity for food 
antigens upon entry. These T cells are 
inactivated and subsequently undergo apoptosis.  
Under physiological conditions, this helps to 
maintain immunological homeostasis.  
However, some hepatic pathogens may gain the 
ability to establish infection in such an 
immunologically tolerant environment 11.  
 
The liver is a major replication site for HCV12. 
Upon infection, hepatocytes may die in an 
apoptotic or necrotic manner. This phenomenon 
is clinically recognized as liver inflammation 
and fibrosis 12.  In addition to this major site of 
replication, alternative sites have been 
recognized. It has been reported that peripheral 
blood mononuclear cells, monocytes, and B and 
T lymphocytes are also sites for the replication 
of HCV13.  
 
APOPTOTIC FACTORS 
Fas-FasL Interactions 
Apoptosis is a cell-intrinsic mechanism that 
triggers cell suicide through a variety of cellular 
signaling pathways14. The process of apoptosis 
involves nuclear condensation, fragmentation, 
and packaging of the deceased cell into 
apoptotic bodies14. These apoptotic bodies are 
subsequently removed by phagocytic cells14. 
Activation of immune responses is circumvented 
by the process of apoptosis14. Unlike apoptosis, 
necrosis results in vacuolation of the cytoplasm, 
degradation of the plasma membrane, and 
release of cellular contents14. This process has 
been reported to induce inflammation around the 
necrotic cell, due to the release of the cell 
contents and proinflammatory molecules14. 
Apoptosis of hepatocytes and leukocytes seems 
to be a key element in the pathogenesis of 
chronic HCV infection 15.  Even though the 
process of apoptosis is usually considered a 
defense mechanism used by host cells, in 
chronic HCV infection this may actually be a 
viral shedding mechanism used by HCV 16.   
A membranous protein belonging to the family 
of tumor necrosis factor (TNF) receptors called 
Fas receptor has been found to trigger a major 
cell pathway of apoptosis. This occurs by the 
binding of Fas to a particular ligand, which 
causes activation of the pathway. Fas is 
inherently expressed in small amounts in 
hepatocytes. However, its expression in HCV-
infected hepatocytes is increased significantly15. 
This increase in Fas expression results in an 
increase in the elimination of hepatocytes15. The 
particular ligand that participates in binding to 
Fas is called FasL. FasL is part of the family of 
TNF ligands, and is expressed on the surface of 
leukocytes, as well as on lymphocytes that 
ultimately infiltrate liver tissue. It is thought that 
Fas-FasL interactions may be responsible for an 
increase in apoptosis of hepatocytes in HCV 
infection 15.  
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There is a high risk of progression towards 
chronic liver inflammation and damage resulting 
from the hepatocytotoxicity that is mediated by 
T lymphocytes (T cells) 17. The ability of the 
immune system to clear HCV infection often 
fails due to an intermediate cytotoxic T-cell 
response18. In this response, T cells are unable to 
eliminate HCV infection, and simultaneously 
cause hepatocyte destruction 18.  
 
It has also been reported that T-cell apoptosis in 
both CD4+and CD8+ lymphocytes can occur as a 
result of the influences of HCV proteins15. FasL 
ligand expression on hepatocytes can be 
amplified by HCV proteins, while in turn Fas 
expression is amplified (by the virus) on CD4+ 
and CD8+ lymphocytes. This can over time 
result in the impairment of immune responses 
through the insufficient elimination of infected 
cells, thereby leading to persistent HCV 
infection 19. Increased expression of Fas on 
leukocytes can cause an increase in the 
susceptibility of immune cells to apoptosis, 
subsequently causing immunological 
impairment15. Over time, this impairment can 
inhibit the elimination of infected hepatocytes, 
thus allowing HCV to persist in host cells, and 
cause chronic infection 15.  
 
Apoptosis Inhibitor of Macrophages 
A recent study has brought to light yet another 
molecular mechanism that may contribute to 
advanced hepatic fibrosis. Apoptosis inhibitor of 
macrophage (AIM) belongs to the scavenger 
receptor cysteine-rich superfamily 20, and is 
secreted exclusively by tissue macrophages 21. 
AIM has shown a positive association with 
hepatic fibrosis 8. Initially, AIM was identified 
as a defense mechanism, providing protection 
from apoptosis for macrophages 20. However, 
serum AIM levels in patients with severe HCC 
seem to be higher than levels tested in patients 
with no or mild hepatic fibrosis 8. It appears that 
as the severity of fibrosis increases, so too do the 
serum AIM levels. Although this mechanism 
remains somewhat unclear, the possibility of 
revealing another marker to test the state of 
hepatic fibrosis that results from chronic HCV 
infection may aid in further understanding the 
pathways that lead to the progression of this 
disease.  
 
INFLAMMATORY MEDIATORS 
The Pivotal Role of Interleukin-1β 
Liver disease progression that is mediated by 
HCV infection has a strong association with 
persistent inflammation 22. An increase in the 
expression of inflammatory cytokines and 
chemokines is fundamental to the disease 
process; this can happen through direct signals 
as well as by recruiting immune cells 23. 
Interleukin-1β (IL-1β) plays a distinctive role in 
the induction of inflammation, and in the 
progression of disease.  
 
Inflammasomes are the activating platforms of 
IL-1β 24. They comprise a family of cytoplasmic 
pattern recognition receptors (PRRs) that are 
altogether known as Nod-like receptors (NLRs), 
and are known to sense viral nucleic acids and 
proteins 24. Upon activation, NLRs form a multi-
protein complex that includes pro-caspase-1. 
Following cleavage of pro-caspase-1 into fully 
functional mature caspase-1, this molecule is 
responsible for the cleavage of IL-1β. Studies 
have shown that Nod-like receptors such as 
NLRP1, NLRP3, and NLRC4 can sense viral 
infections1. This leads to the activation of 
inflammasomes, and ultimately to the release of 
the proinflammatory cytokines IL-1β and IL-18 
1
.  The activation and subsequent release of these 
cytokines are strictly regulated processes, which 
require two distinct signals25. The first signal 
occurs in a TLR signal-dependent fashion. 
NFκB is activated, and in turn synthesizes pro-
IL-1β and pro-IL-18 mRNAs1. The activation of 
caspase-1 is involved in the second signal. 
Caspase-1 is responsible for the cleavage of pro-
IL-1β as well as pro-IL-18 into their mature 
forms 1.  
 
Studies have shown that HCV induces the 
production and secretion of IL-1β26. It appears 
that several cell types in the liver participate in 
IL-1β production as a result of HCV infection. 
Hepatic macrophages within HCV-infected liver 
tissues have been found to produce IL-1β in 
high concentrations 4. Between 80% and 90% of 
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tissue macrophages in the body consist of 
Kupffer cells, which reside in liver tissue 27. 
PRRs on the surface of Kupffer cells have the 
ability to sense HCV; in turn Kupffer cells can 
inflict inflammatory responses 28. Specifically, 
the production of inflammatory cytokines TNF-
α and IL-1β occurs in Kupffer cells as a result of 
induction by nonstructural viral proteins NS3, 
NS4, and NS5 3.  
 
Hepatic stellate cells (which comprise of 5-8% 
of total cells in the liver 29) also secrete IL-1β. 
This induces the production of pro-inflammatory 
cytokines and chemokines IL-6 and IL-8 18.  
Additionally, HCV has the ability to activate the 
Nod-like receptor P3 (NLRP3) inflammasome 
complex26.  The synthesis of proinflammatory 
cytokines and chemokines can result from the 
induced production of IL-1β via activated 
NLRP3 26.  
 
SHIP TLR Pathway Inhibitor  
Various cytokines, chemokines, and 
transcription factors contribute to chronic 
inflammation. This can be described as a 
continuous active inflammatory response and 
tissue destruction, which subsequently leads to 
irreversible tissue remolding 30. Persistent 
inflammation is a major determining factor in 
the progression of liver fibrosis in chronic HCV 
infection. It has been reported that this 
inflammation is subject to regulation by 
components of the innate immune system 
through toll-like receptor (TLR) signaling31. 
Activation of TLR pathways trigger the 
production of proinflammatory cytokines when 
challenged with specific ligands such as HCV 
proteins, dsRNA, and ssRNA 31. In turn, TRLs 
will subsequently activate NFκB, which is 
responsible for the transcription of inflammatory 
genes 4. Viral proteins core and NS3 have been 
found to activate TLR2 31. Studies have also 
shown a correlation between the regulation of 
gene expression in a TLR2/TLR4 inhibitor 
called inositol polyphosphate-5-phosphatase 
(INPP5D, or SHIP) and an endogenous TLR4-
ligand, heat shock protein 8 (HSPB8) 32. Due to 
its anti-inflammatory characteristics, SHIP may 
be involved in the regulation of immune-related 
liver pathogenesis 32. The extent to which the 
TLR system is responsible for the modulation of 
fibrogenic mechanisms and inflammatory 
responses are still not fully understood. 
However, recent studies have generated data 
suggesting a significant inverse correlation 
between the expression of SHIP, HSPB8, and 
the severity of fibrosis in the liver 32. Taken 
together, the increase in biosynthesis of HSPB8 
coupled with the decrease in SHIP expression 
may render those suffering from chronic HCV 
infection more susceptible to severe liver 
fibrosis 32.  
 
GENETIC INSTABILITY 
Activation-Induced Cytidine Deaminase 
One of the most recognized molecules that 
contributes to the pathogenesis of chronic 
inflammation is the transcription factor NF-κB 
30
. In virus-infected cells, NF-κB plays a 
fundamental role in the regulation of cytokines, 
chemokines, and interferons 33. A variety of 
proinflammatory cytokines and microbial 
products are successful activators of this 
transcription factor; in turn, NF-κB has the 
ability to regulate various cytokines and 
chemokines that are determinants of cell fate 34.  
It has been shown that HCV core protein has the 
ability to induce NF-κB activation in 
hepatocytes 35. This particular molecule has 
recently been identified to be responsible for the 
direct activation of the nucleotide-editing 
enzyme activation-induced cytidine deaminase 
(AID) 36. It has been reported that AID is 
directly involved in DNA instability 36. The 
accumulation of genetic alterations in various 
genes can occur as a result of abnormal 
expression of AID in hepatic tissues 37. Due to 
its dangerous capabilities of causing changes to 
somatic DNA, AID is tightly regulated under 
physiological conditions 38. Although under 
physiological conditions AID expression is 
restricted to activated B- cells, the abnormal 
expression of AID results in the accumulation of 
genetic alterations in hepatoma cells; thus 
suggesting a correlation between the 
inappropriate expression of AID and increased 
genetic susceptibility to mutagenesis in 
hepatocytes. It has been reported that through 
the mutagenesis of inappropriate target genes, 
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AID has shown direct oncogenic potential 38.  
This cascade of molecular events may 
subsequently lead to the development of HCC 37.  
 
DISCUSSION 
There are a plethora of molecular mechanisms 
that appear to feed into the sustained 
inflammatory condition that is a hallmark of 
chronic HCV infection. Other factors such as 
apoptotic pathways and genetic alterations also 
play pivotal roles in the progression of the 
diseased state. A multitude of molecular 
mechanisms are deregulated in the host, and 
both innate and adaptive immune components 
are affected.  
The presence of persistent inflammation is a key 
determinant in the progression of liver fibrosis in 
chronic HCV infection. Increased expression of 
inflammatory cytokines, chemokines, and 
transcription factors are essential in the 
progression of disease. This expression can 
occur as a result of direct signaling, as well as 
indirect molecular pathways, some of which are 
virus-mediated. HCV can induce the production 
and secretion of IL-1β. Several cell types take 
part in HCV-triggered IL-1β production, part in 
HCV-triggered IL-1β production, including 
Kupffer cells and hepatic stellate cells. HCV is 
also responsible for the activation of the Nod-
like receptor, NLRP3, which in turn will activate 
the inflammasome complex, a cascade that 
ultimately ends in the production of mature, 
biologically active IL-1β. 
Although under physiological conditions 
apoptosis is considered a host defense 
mechanism, in the case in chronic HCV 
infection, this would-be host defense turns on 
itself, and apoptotic events appear to be critical 
in disease progression. These events can be 
mediated by several mechanisms, including Fas-
FasL interactions as well as apoptosis inhibitor 
of macrophages (AIM).  Fas-FasL interactions 
can either result in the elimination of 
hepatocytes, or of T lymphocytes; both cases 
result in the impairment of immune responses, 
by which host defenses are unable to adequately 
eliminate HCV-infected cells. In AIM, the 
protection from apoptotic events in macrophages 
causes serum AIM levels to rise; this correlates 
with increasing severity in fibrosis. 
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